Muscular Dystrophy - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 144
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M0633E79524EN
Leaflet:

Download PDF Leaflet

Muscular Dystrophy - Pipeline Review, H2 2016
Muscular Dystrophy - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy – Pipeline Review, H2 2016, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 24 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 4 molecules, respectively.Muscular Dystrophy.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Muscular Dystrophy Overview
Therapeutics Development
Pipeline Products for Muscular Dystrophy - Overview
Pipeline Products for Muscular Dystrophy - Comparative Analysis
Muscular Dystrophy - Therapeutics under Development by Companies
Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes
Muscular Dystrophy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Muscular Dystrophy - Products under Development by Companies
Muscular Dystrophy - Products under Investigation by Universities/Institutes
Muscular Dystrophy - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
AMO Pharma Limited
Asahi Kasei Pharma Corp.
aTyr Pharma, Inc.
Benitec Biopharma Limited
Bio Blast Pharma Ltd.
Biophytis SAS
Corcept Therapeutics Incorporated
Evotec AG
F. Hoffmann-La Roche Ltd.
Genethon
Ionis Pharmaceuticals, Inc.
Marina Biotech, Inc.
Medestea Research & Production S.p.A.
Novogen Limited
Pfizer Inc.
Prothelia, Inc.
SanBio, Inc.
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics, Inc.
Selecta Biosciences, Inc.
Strykagen Corporation
Takeda Pharmaceutical Company Limited
WAVE Life Sciences Ltd.
Muscular Dystrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACE-083 - Drug Profile
Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile
Antisense RNAi Oligonucleotides for Myotonic Dystrophy - Drug Profile
ATYR-1940 - Drug Profile
baliforsen - Drug Profile
BIO-103 - Drug Profile
domagrozumab - Drug Profile
Drugs for Merosin-Deficient Congenital Muscular Dystrophy Type 1A - Drug Profile
elcatonin - Drug Profile
Gene Therapy for Muscular Dystrophy and Liver Diseases - Drug Profile
Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies - Drug Profile
Gene Therapy to Activate Dysferlin for Dysferlinopathies - Drug Profile
Gene Therapy to Activate Dystrophin for Muscular Dystrophy - Drug Profile
IUCT-169 - Drug Profile
IUCT-290 - Drug Profile
IUCT-309 - Drug Profile
ketoprofen - Drug Profile
LR-08 - Drug Profile
MED-1101 - Drug Profile
mexiletine hydrochloride - Drug Profile
Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy - Drug Profile
Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile
omigapil - Drug Profile
Pabparna - Drug Profile
poloxamer - Drug Profile
PRT-01 - Drug Profile
Recombinant Protein to Activate Utrophin for Muscular Dystrophies - Drug Profile
RNAi Gene Therapy to Inhibit Myotilin for LGMD - Drug Profile
RP-33 - Drug Profile
SB-308 - Drug Profile
SIWA-318 - Drug Profile
Small Molecule to Inhibit DUX4 for Muscular Dystrophy - Drug Profile
Small Molecule to Target CUG RNA for Myotonic Dystrophy 1 - Drug Profile
Small Molecule to Target RNA for Myotonic Dystrophy - Drug Profile
Small Molecules for Dysferlinopathies - Drug Profile
Small Molecules for Facioscapulohumeral Muscular Dystrophy - Drug Profile
Small Molecules for Myotonic Dystrophy - Drug Profile
Small Molecules for Myotonic Dystrophy Type 1 - Drug Profile
Small Molecules to Activate SMCHD1 for Facioscapulohumeral Dystrophy - Drug Profile
Small Molecules to Antagonize Glucocorticoid Receptor II for Muscular Dystrophy - Drug Profile
Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I - Drug Profile
Small Molecules to Target RNA for Myotonic Dystrophy - Drug Profile
SRT-149 - Drug Profile
SRT-152 - Drug Profile
Stem Cell Therapy for Muscular Dystrophy - Drug Profile
Stryka-232 - Drug Profile
Stryka-234 - Drug Profile
Stryka-425 - Drug Profile
Stryka-533 - Drug Profile
Stryka-978 - Drug Profile
tideglusib - Drug Profile
trehalose - Drug Profile
TXA-127 - Drug Profile
VAL-0411 - Drug Profile
VAL-1205 - Drug Profile
Muscular Dystrophy - Dormant Projects
Muscular Dystrophy - Discontinued Products
Muscular Dystrophy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 140

LIST OF TABLES

Number of Products under Development for Muscular Dystrophy, H2 2016
Number of Products under Development for Muscular Dystrophy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H2 2016
Muscular Dystrophy - Pipeline by AMO Pharma Limited, H2 2016
Muscular Dystrophy - Pipeline by Asahi Kasei Pharma Corp., H2 2016
Muscular Dystrophy - Pipeline by aTyr Pharma, Inc., H2 2016
Muscular Dystrophy - Pipeline by Benitec Biopharma Limited, H2 2016
Muscular Dystrophy - Pipeline by Bio Blast Pharma Ltd., H2 2016
Muscular Dystrophy - Pipeline by Biophytis SAS, H2 2016
Muscular Dystrophy - Pipeline by Corcept Therapeutics Incorporated, H2 2016
Muscular Dystrophy - Pipeline by Evotec AG, H2 2016
Muscular Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Muscular Dystrophy - Pipeline by Genethon, H2 2016
Muscular Dystrophy - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
Muscular Dystrophy - Pipeline by Marina Biotech, Inc., H2 2016
Muscular Dystrophy - Pipeline by Medestea Research & Production S.p.A., H2 2016
Muscular Dystrophy - Pipeline by Novogen Limited, H2 2016
Muscular Dystrophy - Pipeline by Pfizer Inc., H2 2016
Muscular Dystrophy - Pipeline by Prothelia, Inc., H2 2016
Muscular Dystrophy - Pipeline by SanBio, Inc., H2 2016
Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016
Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2016
Muscular Dystrophy - Pipeline by Selecta Biosciences, Inc., H2 2016
Muscular Dystrophy - Pipeline by Strykagen Corporation, H2 2016
Muscular Dystrophy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Muscular Dystrophy - Dormant Projects, H2 2016
Muscular Dystrophy - Dormant Projects (Contd..1), H2 2016
Muscular Dystrophy - Discontinued Products, H2 2016 127

LIST OF FIGURES

Number of Products under Development for Muscular Dystrophy, H2 2016
Number of Products under Development for Muscular Dystrophy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Duchenne Muscular Dystrophy - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 283 pages

Ask Your Question

Muscular Dystrophy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: